Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
about
Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous TocilizumabTreatment of early-stage HER2+ breast cancer-an evolving fieldSubcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German CentersTime Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight CountriesLong-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast CenterTargeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Trastuzumab in advanced breast cancer--a decade of experience in GermanyThe optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectivesA time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer.Subcutaneous trastuzumab: drug development and current position.Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.Adjuvant systemic therapy in breast cancer: quo vadis?Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.Trastuzumab in the Treatment of Breast Cancer.Adjuvant trastuzumab: a 10-year overview of its benefit.Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation.Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance.Subcutaneous Administration of Monoclonal Antibodies in Oncology.Trial Watch: Radioimmunotherapy for oncological indications.Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.Measuring tissue back-pressure--in vivo injection forces during subcutaneous injection.
P2860
Q28080677-5F5BBCCC-7651-4A25-978B-6485738E5CACQ28081124-53E6FBBD-2B3B-43C8-AEE9-B5AF25EA43E2Q28083633-39DF564B-F68D-47B1-B6F8-22EA15253724Q28552256-D2F90EF8-C694-43B8-ACF1-ED48E45B7D11Q30371966-669D88AE-54D9-4E7B-BFB9-EB2E9694237AQ33800955-8788143E-B781-4448-9A77-009879B0B970Q34042715-4D2D97CE-DA2A-4592-B7A1-274C1BAD7926Q34969710-46EA7F50-E886-48C2-8555-7DD0CCE437ABQ35827701-94E7CD71-AF3F-4761-AE57-11E58AC26B45Q35871467-0EB069B8-25B6-42DD-B500-5D87565A6047Q35914396-D617ADA5-9E69-44F7-BA1E-8DA9122ED1C4Q36243612-F9CCA6CF-C53E-40DB-A941-6E64801BEFE1Q36360553-290DCFBA-9300-4051-924B-474717B3EAA4Q36677415-381A3094-1339-40D5-9B39-AFACAE6A7FE2Q36706854-5E2F9E4C-59AC-417E-AC2F-DA2AFF25BC25Q38198973-E24C0455-8C70-4185-A4ED-973F1AC0E5A6Q38207920-01BA09DE-FD0B-4231-AC31-ACA30EB3F348Q38228519-13521BDD-4BAC-4412-B077-E6290CEEC575Q38257642-C924B13D-9329-4F2F-82E3-058A3115662EQ38364913-C7580C8A-8635-4298-B46B-87723145ABADQ38657864-9940084A-7487-45D4-8CA1-207EB398388AQ38728589-C435F7AF-1A50-48FF-8C2C-D16836555289Q38739914-E90C89AF-081B-40CF-842E-A09934BD04BBQ39018742-013AE968-A247-4DB2-910B-022771B6A694Q39066090-1E0FD72C-ED00-4512-AAB9-061C459A39E1Q41125390-B755AB2C-B0CD-4673-BAAF-0648CC0F3AA8Q41658299-BBB30B16-0896-422C-AF1B-2F4D97A48F4FQ41710814-6B8AF194-ECBC-413A-B39D-48D5972BBA8FQ41772666-76376252-6EE3-4FAF-8741-A106E8DF9B50Q42065760-091A5624-0C94-4B56-B08D-AE3D77F88EA6Q43104064-C08AB81F-BEA5-4BD9-B2EB-1BDC0C3A8606Q43243759-5D49E4D4-7A9F-4BA1-BFB6-1F32771B7BD3Q43924146-0BAE1716-B28C-499A-83E0-F51E0B3CE427Q47109682-721AEA7D-6AEA-4A95-93A9-541BC35492A1Q47149669-EC995B1B-C642-4D4A-9769-4510EF52B0E3Q49330618-1C15728B-7C4D-4E18-8EF4-6E1B2241A598Q49881176-03C0F76C-7CC9-4325-8E71-45EBD79CF1F2Q50595872-41BDBBB9-0B65-4474-8BFB-5E4D79CEA7B2Q53086305-5371B5B8-4FCA-4822-8CB0-5DC2FDF0F82DQ53354258-F147251B-D853-4BD2-B9E3-8ABBE2B9DA64
P2860
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Preference for subcutaneous or ...... n open-label randomised study.
@en
Preference for subcutaneous or ...... 2-positive early breast cancer
@nl
type
label
Preference for subcutaneous or ...... n open-label randomised study.
@en
Preference for subcutaneous or ...... 2-positive early breast cancer
@nl
prefLabel
Preference for subcutaneous or ...... n open-label randomised study.
@en
Preference for subcutaneous or ...... 2-positive early breast cancer
@nl
P2093
P50
P1433
P1476
Preference for subcutaneous or ...... n open-label randomised study.
@en
P2093
Guillermo López-Vivanco
Nana Scotto
PrefHer Study Group
Stuart Osborne
Sunil Verma
Valerie Jenkins
Volkmar Müller
Xavier Pivot
P304
P356
10.1016/S1470-2045(13)70383-8
P50
P577
2013-08-19T00:00:00Z